2022
Reversibility of brain glucose kinetics in type 2 diabetes mellitus
Sanchez-Rangel E, Gunawan F, Jiang L, Savoye M, Dai F, Coppoli A, Rothman DL, Mason GF, Hwang JJ. Reversibility of brain glucose kinetics in type 2 diabetes mellitus. Diabetologia 2022, 65: 895-905. PMID: 35247067, PMCID: PMC8960594, DOI: 10.1007/s00125-022-05664-y.Peer-Reviewed Original ResearchConceptsType 2 diabetesBrain glucose levelsGlucose levelsHyperglycaemic clampGlycaemic controlBrain glucoseUncontrolled type 2 diabetesType 2 diabetes mellitusConclusions/interpretationThese findingsAims/hypothesisWePlasma glucose levelsLinear mixed-effects regression modelsMixed-effects regression modelsContinuous glucose monitoringMinimal weight changeMagnitude of improvementAge 44.8MethodsEight individualsSD HbA1cDiabetes mellitusCerebral glucoseInterpretationThese findingsWeek interventionRegimen intensificationPost intervention
2019
PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes
Bini J, Sanchez-Rangel E, Gallezot JD, Naganawa M, Nabulsi N, Lim K, Najafzadeh S, Shirali A, Ropchan J, Matuskey D, Huang Y, Herold K, Harris PE, Sherwin RS, Carson RE, Cline GW. PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes. Journal Of Nuclear Medicine 2019, 61: 570-576. PMID: 31601695, PMCID: PMC7198375, DOI: 10.2967/jnumed.119.234013.Peer-Reviewed Original ResearchConceptsT1DM individualsHealthy controlsDopamine DOutcome measuresAcute C-peptide responseSUVR-1Type 1 diabetes mellitusPET/CT scanningDuration of diabetesMaximal glycemic potentiationC-peptide responseClinical outcome measuresInsulin secretory capacityRoutine clinical measuresD3 receptor densityΒ-cell functionC-peptide releaseQuantitative PET measuresΒ-cell massDynamic PET scansQuantitative outcome measuresAgonist PET radioligandDiabetes mellitusReceptor agonistInsulin antibodies